Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2026Revista Brasileira de Farmacognosia

Myricetin pretreatment protects cardiac cells against doxorubicin-induced cardiotoxicity by reducing inflammation and apoptosis.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The clinical use of doxorubicin is restricted by serious cardiotoxic side effects, prompting investigation into whether myricetin protects against doxorubicin-induced cardiotoxicity and its underlying molecular mechanisms.

Does myricetin pretreatment prevent doxorubicin-induced cardiotoxicity in H9C2 cardiac cells?

Population

Cultured H9C2 cardiomyocyte cell line

Comparison

Pretreatment with myricetin (0.25, 0.5, and 1 µM) before doxorubicin vs doxorubicin alone

Design

In vitro controlled laboratory study

Follow-up

24 h

Key result

Myricetin pretreatment protected H9C2 cardiac cells against doxorubicin-induced cardiotoxicity by increasing cell viability, enhancing antioxidant defense, and reducing inflammation and apoptosis.

Authors

AAAzadeh AminzadehKerman University of Medical SciencesHBHamideh BashiriKerman University of Medical Sciences

Discussion

Loading...

Member takes

Overview

Myricetin shows in vitro promise against doxorubicin cardiotoxicity; leaves open clinical translation pending in vivo studies.

Key Points

  • This study investigates myricetin's protective effects against doxorubicin-induced cardiotoxicity in H9C2 cardiac cells.
  • H9C2 cells were treated with 1 µM doxorubicin for 24 hours to induce cardiac injury.
  • Cell viability was measured with MTT assay, and oxidative stress and inflammatory markers were assessed.
  • Myricetin was administered at doses of 0.25, 0.5, and 1 µM prior to doxorubicin exposure.
  • Doxorubicin decreased cell viability, while myricetin pretreatment significantly increased it.
  • Doxorubicin elevated reactive oxygen species, TNF-α, IL-1β levels, and reduced total antioxidant capacity.
  • Myricetin reduced the BAX/BCL2 mRNA ratio and decreased cleaved caspase-3 expression.

Structured PICO

Does myricetin pretreatment prevent doxorubicin-induced cardiotoxicity in H9C2 cardiac cells?

P
Population
Cultured H9C2 cardiomyocyte cell line
I
Intervention
Myricetin pretreatment (0.25, 0.5, and 1 µM) before doxorubicin treatment
C
Comparator
Doxorubicin (1 µM for 24 h) alone
O
Outcome
Cell viability measured by MTT assaysurrogate

Myricetin pretreatment protects against doxorubicin-induced cardiotoxicity in vitro by enhancing antioxidant defense and reducing inflammatory and apoptotic pathways.

Cite This Study

Aminzadeh et al. (2026) studied Doxorubicin-induced cardiotoxicity. Myricetin vs. Doxorubicin alone was evaluated on Cell viability, oxidative stress, inflammatory markers, and apoptotic pathway. Myricetin pretreatment protected H9C2 cardiac cells against doxorubicin-induced cardiotoxicity by increasing cell viability, enhancing antioxidant defense, and reducing inflammation and apoptosis.

synapsesocial.com/papers/6a13ea020e02ee3982d3372ahttps://doi.org/10.1007/s43450-026-00749-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myricetin Prevents Doxorubicin-Induced Oxidative Stress and Mitochondrial Apoptotic Pathway in H9C2 Cardiac Cells2025
  2. 2Myricitrin Protects against Doxorubicin‐Induced Cardiotoxicity by Counteracting Oxidative Stress and Inhibiting Mitochondrial Apoptosis via ERK/P53 Pathway2016 · 53 citations
  3. 3Cardioprotective potentials of myricetin on doxorubicin-induced cardiotoxicity based on biochemical and transcriptomic analysis2024 · 9 citations
  4. 4In-silico and In-vivo Investigations Reveal Ameliorative Potential of Myricetin Against Doxorubicin-induced Myocardial Damage via Modulation of NF-κB Signaling Pathway2025
  5. 5Protective effect of<i>Mutellina purpurea</i>polyphenolic compounds in doxorubicin-induced toxicity in H9c2 cardiomyocytes2014 · 11 citations